From June 21 to 25, 2025, the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH 2025) was held in Washington, D.C., drawing nearly 6,000 global experts, scholars, and professionals in the field. With its innovative solutions in thrombosis and haemostasis, Wondfo attracted much attention at the conference.
 
As one of the most influential international events in the field, over 70 leading companies from around the globe participated ISTH, presenting their latest scientific achievements.



Wondfo Biotech demonstrated key innovations and localized solutions in thrombosis and haemostasis, contributing to more effective diagnosis and monitoring of related diseases.
 
Driven by global healthcare needs, Wondfo has leveraged its core platforms—fluorescence immunoassay, chemiluminescence, and electrochemical detection—to develop and commercialize a range of diagnostic solutions for sepsis and in-hospital VTE prevention.

Sepsis Diagnostic Solutions
Based on immunofluorescence platform, Wondfo has developed comprehensive panel of infection biomarker (IL-6, CRP, PCT, SAA, and hs-CRP) and introduced China's first early screening panel for thrombosis (TM, TAT, PIC, t-PAIC). These solutions supports early detection, infection differentiation, treatment guidance, and efficacy monitoring for sepsis.



"This is an excellent project. We hope to collaborate on clinical research for acute obstetric coagulation." said a university professor from the UK. Due to its high sensitivity, excellent marker stability, contamination-free operation, wide detection range, simple and rapid operation, and cost-effective instrumentation, Wondfo Biotech's Thrombosis Four-Item Panel testing reagents have been widely adopted in over a thousand medical testing institutions.
 
In-hospital VTE Prevention and Treatment Solution
Combining chemiluminescence and electrochemical platforms, Wondfo has built a flexible and comprehensive coagulation testing solution that addresses the challenges of managing coagulation disorders in critical care.



"Your thromboelastography analyzer is exactly what we need." said a doctor from a U.S. hospital, expressing strong interest in implementing the device.
 
Racing for Life, Wondfo will continue to drive scientific innovation, improving global health and advancing biotechnology to benefit society.